Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-22T08:40:27.220Z Has data issue: false hasContentIssue false
  • English
  • Français

A Comparison of the Effects of Oxypertine and Trifluoperazine in Withdrawn Schizophrenics

Published online by Cambridge University Press:  29 January 2018

P. V. Hunt
P. V. Hunt*
Affiliation:
Atkinson Morley's Hospital, London, S.W.20; Springfield Hospital, London, S. W.17
Get access Rights & Permissions [Opens in a new window]

Extract

There is a growing body of evidence that oxypertine (Win. 18,501), a recently developed indolylalkyl-phenyl-piperazine (1, 9), is of value in the treatment of schizophrenia (6). Oxypertine has been described as superior to trifluoperazine in its effect on certain aspects of schizophrenic behaviour (2, 5).

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 505 , December 1967 , pp. 1419 - 1424
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Archer, S., Wylie, D. W., Harris, L. S., Lewis, T. R., Schulenberg, J. W., Bell, M. R., Kullnig, R. K., and Arnold, A. (1962). “1-(indolylalkyl)-4-arylpiperazines: a new class of tranquillizers.” J. Amer. chem. Soc., 84, 1306.Google Scholar
2. Calwell, W. P. K., Jacobsen, M., and Skarbek, A. (1964). “A comparative study of oxypertine and trifluoperazine in chronic schizophrenia: a new application of the Wing rating scale.” Brit. J. Psychiat., 110, 520–530.CrossRefGoogle Scholar
3. Flament, J., Lofft, J. G., and von Mendelssohn, F. (1964). “Clinical investigation of psycho-pharmacological effects of Win. 18,501-2.” Neuro-Psychopharmacology Proceedings: 3rd International Congress of Collegium Internationale Neuro-Psychopharmacologium, Munich, 1962, 3, 275. Amsterdam: Elsevier.Google Scholar
4. Meyler, L. (1966). In: Side Effects of Drugs, 1963–1965. Excerpta Medica Foundation, 2, 49–56.Google Scholar
5. Skarbek, A., and Hill, G. B. (1967). “An extended trial of oxypertine in five selected cases of chronic schizophrenia.” Brit. J. Psychiat., 113, 1107–1112.CrossRefGoogle Scholar
6. Skarbek, A., and Jacobsen, M. (1965). “Oxypertine: a review of clinical experience.” Brit. J. Psychiat., 111, 1173–1179.Google Scholar
7. Venables, P. H. (1957). “A short scale for rating ‘activity withdrawal’ in schizophrenics.” J. ment. Sci., 103, 197–199.Google Scholar
8. Wing, J. K. (1961). “A simple and reliable subclassification of chronic schizophrenia.” Ibid., 107, 862–875.Google Scholar
9. Wylie, D. W., and Archer, S. (1962). “Structure-activity relationships of 1-((3-indolyl) alkyl)-4-aryl-piperazines, a new series of tranquillizers.” J. med. pharm. Chem., 5, 932–943.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.